Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer-Reference-Cited by-同舟云学术

Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer

Published:2011-07 Issue:7 Volume:13 Page:499-503
ISSN:1699-048X
Container-title:Clinical and Translational Oncology
language:en
Short-container-title:Clin Transl Oncol

Author:

Asher Viren,Lee Joanne,Innamaa Anni,Bali Anish

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12094-011-0687-9.pdf

Reference30 articles.

1. Cancer Research UK (2006) Ovarian cancer incidence statistics. Cancer Research UK. Available from: http://info.cancerresearchuk.org/cancerstats/types/ovary/incidence/index.htm

2. Horner MJ, Ries LAG, Krapcho M et al (eds) (2009) SEER cancer statistics review, 1975–2006. Available from: http://seer.cancer.gov/csr/1975_2006/

3. Jemal A, Siegel R, Ward E et al (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225–249

4. Marchetti C, Pisano C, Facchini G et al (2009) First-line treatment of advanced ovarian cancer: current research and perspectives. Exp Rev Anticancer Ther 10:47–60

5. Ozols RF (2006) Challenges for chemotherapy in ovarian cancer. Ann Oncol 17[Suppl 5]:v181–187

Cited by 221 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early prediction of ovarian cancer risk based on real world data;2024-07-27

2. Predictive value of serum inflammatory markers in retinopathy of prematurity;Eye;2024-07-25

3. Preoperative Laboratory Values Predicting Periprosthetic Joint Infection in Morbidly Obese Patients Undergoing Total Hip or Knee Arthroplasty;Journal of Bone and Joint Surgery;2024-06-28

4. Prognostic value of systemic inflammation response indexes obtained from the complete blood count in patients treated for advanced ovarian carcinoma in front line;Clinical and Translational Oncology;2024-06-10

5. Development and Validation of a Prognostic Nomogram for HR+ HER- Breast Cancer;Cancer Management and Research;2024-05